Non-invasive Prenatal Testing (NIPT) Market Size, Share, Growth, and Industry Analysis, By Type (Ultrasound,NGS,PCR,Microarray), By Application (Hospital,Diagnostic Labs), Regional Insights and Forecast to 2035

Non-invasive Prenatal Testing (NIPT) Market Overview

The global Non-invasive Prenatal Testing (NIPT) Market size is projected to grow from USD 3734.97 million in 2026 to USD 4172.34 million in 2027, reaching USD 10115.55 million by 2035, expanding at a CAGR of 11.71% during the forecast period.

The Non-invasive Prenatal Testing (NIPT) Market has grown significantly, with more than 9.8 million tests performed globally in 2024, compared to 5.5 million in 2019. Adoption has increased across 120 countries, with accuracy rates of over 99.9% for trisomy 21 and 97.8% for trisomy 13. More than 67% of high-risk pregnancies worldwide undergo NIPT screening, while 36% of low-risk pregnancies now include NIPT as part of early prenatal care. Global prevalence of Down syndrome is approximately 1 in 700 births, fueling demand for reliable testing. More than 600 laboratories worldwide now provide advanced NIPT services using sequencing and bioinformatics.

The United States is a leader in the Non-invasive Prenatal Testing (NIPT) Market, performing over 1.5 million tests annually. Out of 4.2 million pregnancies per year, approximately 35% undergo NIPT screening. The prevalence of chromosomal abnormalities is 1 in 160 pregnancies, making testing a clinical priority. More than 50 laboratories in the U.S. are accredited for NIPT, with FDA-approved platforms ensuring widespread adoption. Data from 25,000 clinical trial participants confirm NIPT’s accuracy exceeding 99.2% for trisomy detection. In the U.S., NIPT use among high-risk pregnancies exceeds 70%, demonstrating strong market penetration.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 72% of NIPT demand is driven by rising maternal age over 35 years.
• Major Market Restraint: 48% of healthcare providers cite affordability and limited reimbursement as barriers.
• Emerging Trends: 61% of research focuses on microdeletion and single-gene disorder testing.
• Regional Leadership: 46% of the global market share is held by North America.
• Competitive Landscape: 39% of global test volumes are dominated by Illumina and Roche combined.
• Market Segmentation: 54% of NIPT tests are performed in diagnostic laboratories.
• Recent Development: 67% of new product launches focus on whole-genome sequencing.

Non-invasive Prenatal Testing (NIPT) Market Latest Trends

The Non-invasive Prenatal Testing (NIPT) Market Report highlights strong adoption trends driven by technology, demographics, and patient awareness. In 2024, 22% of new NIPT launches incorporated whole-genome sequencing compared to 8% in 2020, increasing test scope beyond common trisomies. Global test sensitivity has improved, with detection rates of 99.9% for trisomy 21, 99.7% for trisomy 18, and 97.8% for trisomy 13. The Non-invasive Prenatal Testing (NIPT) Market Analysis reveals rising adoption among women under 35, where test usage has grown from 21% in 2018 to 36% in 2024.

AI-driven bioinformatics platforms are shaping the Non-invasive Prenatal Testing (NIPT) Market Trends, with 18% of labs worldwide now using machine learning to cut false positives by 40%. Additionally, 120+ new hospital-laboratory partnerships were formed globally between 2023–2024, boosting accessibility. The Non-invasive Prenatal Testing (NIPT) Market Insights indicate rapid adoption in Asia-Pacific, where annual test volumes reached 2.1 million. By expanding clinical applications and leveraging data analytics, the Non-invasive Prenatal Testing (NIPT) Market Forecast points toward accelerated test integration across both high-risk and general pregnancies.

Non-invasive Prenatal Testing (NIPT) Market Dynamics

DRIVER

"Rising maternal age and genetic disorder prevalence"

Globally, 12% of pregnancies occur in women aged 35+, compared to 8% two decades ago. This increases the risk of chromosomal abnormalities, as Down syndrome risk rises to 1 in 100 pregnancies at age 40+ compared to 1 in 1,500 pregnancies at age 20. In Europe alone, 350,000 high-risk pregnancies are recorded annually, creating strong demand. The Non-invasive Prenatal Testing (NIPT) Market Growth is fueled by this demographic shift, with 88% of high-risk mothers choosing NIPT over invasive procedures.

RESTRAINT

"Limited reimbursement and affordability issues"

The Non-invasive Prenatal Testing (NIPT) Market Research Report highlights affordability gaps. Approximately 52% of healthcare providers in developing regions identify high test costs as a barrier. In India, fewer than 10% of pregnant women access NIPT due to limited insurance. In the U.S., only 38% of insurance plans cover NIPT for low-risk pregnancies. This restricts the overall Non-invasive Prenatal Testing (NIPT) Market Size, particularly in emerging economies.

OPPORTUNITY

"Expansion into microdeletion and monogenic disorder testing"

The Non-invasive Prenatal Testing (NIPT) Market Opportunity lies in extending applications. More than 45 clinical studies since 2023 focus on microdeletions like DiGeorge syndrome, affecting 1 in 4,000 births. By 2026, 30% of NIPT panels are expected to include monogenic disorders. With 5 million annual monogenic disease cases worldwide, this diversification represents significant growth. Laboratories in China, Europe, and the U.S. are pioneering genome-wide NIPT platforms with advanced algorithms.

CHALLENGE

"Variability in regulatory approvals"

The Non-invasive Prenatal Testing (NIPT) Market Challenges stem from uneven regulation. In Europe, only 15 countries have nationwide NIPT guidelines. In the U.S., FDA approvals cover laboratory-developed tests (LDTs), but state policies vary. In Japan, only 190 hospitals out of 8,000 are licensed to offer NIPT. This regulatory inconsistency limits Non-invasive Prenatal Testing (NIPT) Market Outlook projections for uniform adoption.

Non-invasive Prenatal Testing (NIPT) Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

By Type

• Ultrasound: Ultrasound continues to play a crucial role in the Non-invasive Prenatal Testing (NIPT) Market, serving as a primary first-trimester screening method. More than 70% of pregnancies worldwide undergo ultrasound scans, with over 6.5 million screenings annually focusing on early markers like nuchal translucency.
• Next-Generation Sequencing (NGS): NGS-based platforms dominate the Non-invasive Prenatal Testing (NIPT) Market Share, accounting for 65% of global testing volume in 2024. These solutions offer unmatched accuracy, with detection of trisomy 21 at 99.9% sensitivity and trisomy 18 at 99.7%. More than 500 laboratories worldwide currently employ NGS-driven prenatal testing, and in the U.S. alone, over 40% of pregnant women at high risk rely on sequencing-based results.
• Polymerase Chain Reaction (PCR): PCR-based NIPT solutions are increasingly deployed in cost-sensitive markets where sequencing technologies may not be widely accessible. PCR accounted for approximately 22% of NIPT tests in 2024, with over 1.4 million annual uses across Asia-Pacific alone. PCR assays achieve 96% sensitivity for trisomy 21, making them highly reliable for targeted screening. In India, more than 35,000 PCR-based NIPT tests are performed annually due to their affordability compared to sequencing.
• Microarray: Microarray adoption in the Non-invasive Prenatal Testing (NIPT) Market Analysis has expanded significantly, accounting for 13% of total global tests in 2024. Microarray platforms analyze large sets of SNPs (single nucleotide polymorphisms), enabling high-resolution detection of genetic variations and microdeletions with 92% sensitivity. More than 250 hospitals in Europe incorporated microarray-based NIPT since 2023, particularly for complex cases requiring comprehensive genetic counseling.

By Application

• Hospitals: Hospitals remain vital end-users in the Non-invasive Prenatal Testing (NIPT) Market, accounting for 46% of global testing volume or approximately 3.5 million annual procedures. Large maternity hospitals in North America, such as those in the U.S. and Canada, report adoption rates exceeding 80% among high-risk pregnancies. European hospitals integrate ultrasound and NIPT in first-trimester programs, performing over 500,000 tests annually. Hospitals also employ certified genetic counselors, providing holistic care and ensuring results are accurately interpreted.
• Diagnostic Laboratories: Diagnostic laboratories dominate the Non-invasive Prenatal Testing (NIPT) Market Segmentation, representing 54% of global testing volume or more than 5.2 million annual cases in 2024. Labs provide centralized, high-throughput sequencing, with 72% of genome-wide NIPT services processed through independent or corporate lab networks. In China, over 300 diagnostic laboratories conduct NIPT, accounting for 1.2 million tests annually. Diagnostic labs also maintain rapid turnaround times, with some facilities delivering results in under 72 hours.

Non-invasive Prenatal Testing (NIPT) Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America leads the Non-invasive Prenatal Testing (NIPT) Market, holding approximately 46% of global share in 2024. The United States conducts more than 1.5 million NIPT tests annually, while Canada contributes over 120,000 screenings each year. In the U.S., adoption exceeds 70% among high-risk pregnancies, and nearly 28% of low-risk pregnancies also use NIPT. More than 50 accredited laboratories in the U.S. and 15 facilities in Canada provide certified services. Clinical studies covering 25,000 women confirm detection accuracy above 99%, reinforcing trust in test reliability. North America benefits from advanced insurance coverage, with more than 60% of private plans covering NIPT for high-risk cases. The Non-invasive Prenatal Testing (NIPT) Market Insights indicate that test adoption is strongest in California, Texas, and New York, which collectively account for 35% of total U.S. test volumes. Canada’s provinces are steadily expanding coverage, with Ontario alone performing 40,000+ annual NIPT tests. With the U.S. focusing on expanding NGS-based testing panels, North America will continue to dominate the Non-invasive Prenatal Testing (NIPT) Market Forecast for at least the next five years.

Europe

Europe contributes around 29% of global NIPT test volumes, representing over 1.8 million annual screenings in 2024. Germany leads the region with approximately 450,000 tests each year, followed by the United Kingdom at 320,000 and France at 280,000. National reimbursement programs exist in 15 European countries, while other regions rely on private healthcare adoption. Adoption among high-risk pregnancies exceeds 75% in France and 69% in the Netherlands, demonstrating strong penetration. The Non-invasive Prenatal Testing (NIPT) Market Analysis notes that over 250 hospitals in Europe have implemented sequencing or microarray-based NIPT. In Italy, more than 100,000 women annually access NIPT, supported by regional health services. Scandinavia maintains some of the highest screening rates, with Denmark reporting 65% adoption across all pregnancies. Eastern Europe lags, with countries like Poland recording fewer than 30,000 tests annually, highlighting a gap in accessibility. The Non-invasive Prenatal Testing (NIPT) Market Trends in Europe point to increasing adoption of genome-wide testing, with more than 40% of labs now offering advanced panels for microdeletion detection. As government programs expand coverage, Europe’s test volume is projected to rise steadily.

Asia-Pacific

The Asia-Pacific region accounts for approximately 21% of the Non-invasive Prenatal Testing (NIPT) Market, performing more than 2.1 million tests annually. China dominates with over 1.2 million screenings per year, supported by more than 300 licensed laboratories. Japan contributes 250,000 annual NIPT tests, though access is restricted to 190 certified hospitals out of 8,000 nationwide. In India, adoption remains limited to fewer than 50,000 annual tests, primarily due to affordability and restricted insurance coverage. Australia and South Korea report higher adoption levels, with more than 40% of high-risk pregnancies undergoing NIPT. In South Korea, around 70,000 tests are performed annually, with demand growing by over 20% in the past three years. Southeast Asia remains a developing market, with countries like Thailand and Malaysia reporting fewer than 15,000 tests annually. The Non-invasive Prenatal Testing (NIPT) Industry Analysis reveals accuracy rates above 99% in Chinese sequencing labs, comparable to Western benchmarks. With rising awareness, expanding private healthcare, and government initiatives, Asia-Pacific is expected to drive future Non-invasive Prenatal Testing (NIPT) Market Growth.

Middle East & Africa

The Middle East & Africa region holds a smaller share, representing only 4% of global NIPT volumes, equivalent to around 400,000 annual tests. The UAE conducts more than 70,000 screenings annually, while Saudi Arabia contributes approximately 110,000 tests per year. South Africa leads within Africa with over 35,000 tests annually, but adoption across Sub-Saharan Africa remains limited. Affordability remains a barrier, as fewer than 15% of pregnant women across the region have access to NIPT services. Despite these challenges, international collaborations have expanded NIPT availability to more than 20 hospitals across the Middle East since 2023. The Non-invasive Prenatal Testing (NIPT) Market Report highlights that Qatar and Kuwait are also increasing adoption, with combined volumes exceeding 25,000 annual tests. In Africa, growth is centered in private hospitals in Nigeria, Kenya, and South Africa, where screening demand is rising by 10% annually. Laboratories in the UAE and Saudi Arabia maintain accuracy rates above 99%, comparable to global leaders. With government focus on maternal health and increasing partnerships with European and U.S. labs, the Non-invasive Prenatal Testing (NIPT) Market Outlook in this region is gradually improving.

List of Top Non-invasive Prenatal Testing (NIPT) Companies

• Illumina
• Qiagen
• Koninklijke Philips
• Pacific Biosciences Of California
• Perkinelmer
• Agilent Technologies
• Hoffman-La Roche
• Thermo Fisher Scientific
• GE Healthcare
• Beijing Genomics Institute

Top Companies with Highest Market Share

• Illumina controls 32% of global test volumes.
• Roche accounts for 25% of diagnostic lab-based NIPT.

Investment Analysis and Opportunities

The Non-invasive Prenatal Testing (NIPT) Market Opportunities are shaped by rising investment in genomic technologies. In 2024, more than $2.5 billion globally was allocated toward expanding genetic testing labs, with 38% directed toward NIPT infrastructure. Over 120 partnerships between hospitals and diagnostic labs have been recorded since 2023, increasing access to advanced testing. Investments in bioinformatics platforms, covering 18% of labs worldwide, have reduced turnaround times from 7 days to 3 days.

Opportunities also arise from expanding NIPT beyond trisomies to microdeletions and monogenic disorders, which represent 5 million annual cases globally. Startups focusing on PCR-based rapid testing received 22% of total funding in 2024, reflecting strong demand for cost-effective solutions. The Non-invasive Prenatal Testing (NIPT) Industry Report highlights growth opportunities in Asia-Pacific, where only 25% of pregnancies currently access NIPT, compared to 65% in developed regions.

New Product Development 

Innovation is central to the Non-invasive Prenatal Testing (NIPT) Market Growth. Illumina launched a sequencing-based test in 2023 with 99.9% accuracy, detecting all 23 chromosomes. Roche introduced a genome-wide NIPT in 2024 targeting 7 microdeletion syndromes. BGI released an AI-integrated platform in 2024, reducing false positives by 35% across 10,000 tests.

Thermo Fisher launched a rapid PCR-based NIPT in 2025 with 48-hour turnaround times. PerkinElmer expanded its NIPT solutions in 2025 to include screening for 5 rare syndromes. These innovations improve accessibility and accuracy, supporting the Non-invasive Prenatal Testing (NIPT) Market Outlook by offering customized solutions.

Five Recent Developments (2023–2025)

• 2023 – Illumina launched NGS-based NIPT with 99.9% trisomy detection.
• 2024 – Roche expanded NIPT services across 25 European hospitals.
• 2024 – BGI introduced AI-driven NIPT reducing false positives by 35%.
• 2025 – PerkinElmer developed a microdeletion-focused test covering 7 syndromes.
• 2025 – Thermo Fisher introduced PCR-based rapid NIPT with 2-day results.

Report Coverage of Non-invasive Prenatal Testing (NIPT) Market 

The Non-invasive Prenatal Testing (NIPT) Market Report provides detailed analysis of market dynamics, segmentation, and competitive landscape. Covering more than 120 countries, the report evaluates adoption rates, test accuracy levels exceeding 99%, and annual volumes surpassing 9.8 million in 2024. The Non-invasive Prenatal Testing (NIPT) Market Research Report examines segmentation by type Ultrasound, NGS, PCR, Microarray and application in hospitals and diagnostic labs.

The Non-invasive Prenatal Testing (NIPT) Industry Report includes regional analysis across North America (46% market share), Europe (29%), Asia-Pacific (21%), and Middle East & Africa (4%). The report tracks competitive performance of leading companies, including Illumina with 32% market share and Roche with 25%. It also covers five key recent developments between 2023–2025. The Non-invasive Prenatal Testing (NIPT) Market Insights highlight investment patterns, new product launches, and regulatory variations across regions.

Non-invasive Prenatal Testing (NIPT) Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 3734.97 Million in 2026
Market Size Value By	USD 10115.55 Million by 2035
Growth Rate	CAGR of 11.71% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Ultrasound NGS PCR Microarray By Application : Hospital Diagnostic Labs
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample